Genexine, Inc.

ACTIVE

4/F B-dong, Korea Bio Park, 京畿道城南市, 京畿道, South Koreawww.genexine.comPublic101–250 employeesEstablished: 1999-06-08

Clinical Trials

17 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

1999

Overview

Trial Phase Distribution

Phase

Trials

Phase 1

70.4%

Phase 2

14.8%

Phase 3

5.6%

Not Applicable

1.9%

Trial Status Distribution

Active, not recruiting

31.5%

Completed

44.4%

No Longer Available

1.9%

Recruiting

3.7%

Terminated

3.7%

Unknown

9.3%

Withdrawn

5.6%

Clinical Trials

Trials sponsored by this organization (54)

Clinical Trial of Efepoetin Alfa in Healthy Subjects

Phase 1

Completed

interventional

Oct 202440 participants

A Phase 3 Study of Efepoetin Alfa for Treatment of Anemia in Patients With Chronic Kidney Disease on Dialysis

Phase 3

Recruiting

interventional

Jan 2024429 participants

Efepoetin alfa for treatment of anemia in chronic kidney disease on dialysis

Phase 1

Active, not recruiting

interventional

Sep 2023429 participants

GX-I7 in Combination With Bevacizumab in Recurrent Glioblastoma (GBM) Patients

Phase 2

Active, not recruiting

interventional

Jan 202220 participants

Evaluation of Efficacy, Safety and Immunogenicity of GX-19N in Healthy Individuals Who Have Received COVID-19 Vaccines

Safety and Preliminary Efficacy Study of GX-I7 in Patients With COVID-19

Phase 1

Terminated

interventional

Mar 202110 participants

Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals

Phase 1

Completed

interventional

Feb 202130 participants

Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults

Phase 1

Completed

interventional

Dec 2020185 participants

Page 1 of 7

Approvals

No approval data available

News

No news articles found

Back to Organizations